The funding deal will support late-stage development of a "pre-pandemic vaccine against H5 influenza virus," Moderna said. But, the deal also includes options for additional vaccine development in case other public health threats arise.
"mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic," Moderna CEO Stéphane Bancel said.
US health officials have said previously that they were in talks with Moderna and Pfizer about the development of a pandemic bird flu vaccine. The future vaccine will be in addition to standard protein-based bird flu vaccines.
[
Collection
]
[
|
...
]